Telemetry Investments’s Neurogene NGNE Stock Holding History

Telemetry Investments’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,274	Closed	-$133K	–	147
2018 Q3	$133K	Buy	+2,274	New	+$134K	0.06%	107

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Telemetry Investments's NGNE Position: Q4 2018 in Review

Telemetry Investments sold out of Neurogene (NGNE) in Q4 2018, closing a stake of 2,274 shares — an estimated $133K sold.

Telemetry Investments first reported a position in NGNE in Q3 2018 and held it in 1 quarter. The position peaked at $133K in Q3 2018. 36 funds tracked by Wall St. Rank hold NGNE as of Q4 2018.

Telemetry Investments reported no remaining Neurogene position as of Q4 2018 after selling out during the quarter.
Telemetry Investments sold 2,274 Neurogene shares in Q4 2018, an estimated $133K.
Telemetry Investments first reported a position in Neurogene in Q3 2018 and held it in 1 quarter.
Telemetry Investments's Neurogene position peaked at $133K in Q3 2018.
36 funds tracked by Wall St. Rank held Neurogene as of Q4 2018.

Based on Telemetry Investments's 13F filing for Q4 2018, filed 14 Feb 2019.